958002-18-1Relevant articles and documents
Finger loop inhibitors of the HCV NS5b polymerase. Part II. Optimization of tetracyclic indole-based macrocycle leading to the discovery of TMC647055
Vendeville, Sandrine,Lin, Tse-I.,Hu, Lili,Tahri, Abdellah,McGowan, David,Cummings, Maxwell D.,Amssoms, Katie,Canard, Maxime,Last, Stefaan,Van Den Steen, Iris,Devogelaere, Benoit,Rouan, Marie-Claude,Vijgen, Leen,Berke, Jan Martin,Dehertogh, Pascale,Fransen, Els,Cleiren, Erna,Van Der Helm, Liesbet,Fanning, Gregory,Van Emelen, Kristof,Nyanguile, Origène,Simmen, Kenny,Raboisson, Pierre
scheme or table, p. 4437 - 4443 (2012/07/17)
Optimization of a novel series of macrocyclic indole-based inhibitors of the HCV NS5b polymerase targeting the finger loop domain led to the discovery of lead compounds exhibiting improved potency in cellular assays and superior pharmacokinetic profile. F
CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS
-
Page/Page column 58-59, (2009/06/27)
The invention encompasses compounds of formula (I) as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV
Compounds for the Treatment of Hepatitis C
-
Page/Page column 30, (2009/05/28)
The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.